Jpmorgan Chase & CO Ice Cure Medical Ltd. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Ice Cure Medical Ltd. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 5,950 shares of ICCM stock, worth $3,450. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,950
Previous 5,950
-0.0%
Holding current value
$3,450
Previous $4,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ICCM
# of Institutions
15Shares Held
294KCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il170KShares$98,3160.0% of portfolio
-
Ubs Group Ag59.9KShares$34,7380.0% of portfolio
-
Virtu Financial LLC New York, NY27.2KShares$15,7690.0% of portfolio
-
Geode Capital Management, LLC Boston, MA25.6KShares$14,8240.0% of portfolio
-
Two Sigma Investments, LP New York, NY18.5KShares$10,7440.0% of portfolio
About IceCure Medical Ltd.
- Ticker ICCM
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 36,835,600
- Market Cap $21.4M
- Description
- IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.